Ganna Sourab, Rahimi Sama, Lu Anh, Laborde Krista, Trivedi Meghana
Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, 77204, USA.
West Penn Hospital, Pittsburg, PA, 15224, USA.
J Cancer Surviv. 2025 Jun;19(3):930-939. doi: 10.1007/s11764-023-01513-y. Epub 2024 Jan 17.
Oral endocrine therapy (OET) is recommended in prevention and treatment of hormone receptor-positive breast cancer (HR+ BC). Despite the reduced incidence, recurrence, and mortality, OET adherence is poor in this patient population. The aim of this study was to review the latest literature to identify effective interventions to improve medication adherence in patients taking OET for prevention or treatment of HR+ BC.
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) framework was used to perform this review. We utilized PubMed, SCOPUS, EMBASE, Cochrane, and Web of Science to acquire articles using search terms including breast cancer, adherence, persistence, and acceptability. Inclusion criteria included publication in peer-reviewed journal, primary data source, longitudinal, patients on OET such as aromatase inhibitors (AIs) or selective estrogen receptor modulators (SERMs), measuring adherence, persistence, or acceptability.
Out of 895 articles identified, 10 articles were included. Majority of patients had early-stage HR+ BC. Two out of two studies incorporating technological intervention, two out of three studies with text communication-based intervention, and three out of five studies with verbal communication-based intervention reported significant improvement in OET adherence and/or persistence.
While the interventions tested so far have shown to improve OET adherence in HR+ BC patients in some studies, there is a need to design combination interventions addressing multiple barriers in this population.
This study showcases effectiveness of novel interventions to improve OET adherence and the need to further develop patient-centered strategies to benefit all patients with HR+ BC.
口服内分泌治疗(OET)被推荐用于激素受体阳性乳腺癌(HR+ BC)的预防和治疗。尽管发病率、复发率和死亡率有所降低,但该患者群体中OET的依从性较差。本研究的目的是回顾最新文献,以确定有效的干预措施,提高接受OET预防或治疗HR+ BC患者的药物依从性。
采用系统评价和Meta分析的首选报告项目(PRISMA)框架进行本综述。我们利用PubMed、SCOPUS、EMBASE、Cochrane和科学网,使用包括乳腺癌、依从性、持续性和可接受性等检索词获取文章。纳入标准包括在同行评审期刊上发表、原始数据源、纵向研究、接受OET(如芳香化酶抑制剂(AIs)或选择性雌激素受体调节剂(SERMs))治疗的患者、测量依从性、持续性或可接受性。
在识别出的895篇文章中,纳入了10篇。大多数患者患有早期HR+ BC。两项纳入技术干预的研究中有两项、三项基于文本交流干预的研究中有两项以及五项基于口头交流干预的研究中有三项报告OET依从性和/或持续性有显著改善。
虽然迄今为止测试的干预措施在一些研究中已显示可提高HR+ BC患者的OET依从性,但仍需要设计综合干预措施来解决该人群中的多重障碍。
本研究展示了新型干预措施提高OET依从性的有效性,以及进一步制定以患者为中心的策略以使所有HR+ BC患者受益的必要性。